Argenx S.E

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
  • TickerARGX
  • ISINNL0010832176
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

Thanks to a better fundamental star rating, ARGENX SE sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ARGENX SE (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 17, 2019, the closing price was EUR 115.70 and its expected value was estimated at EUR 110.41.

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Analyst Day Up Next for Discussion on New Pipeline Candidates

Alan Vandenberghe ...
  • Alexander Makar
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: ARGX BB, BAMNB NA, BEKB BB, BOKA NA, CYAD BB, EVS BB, GBLB BB, ONTEX BB, QRF BB

Argenx: 1Q19 – further de-risking pipeline with 2 additions BAM Group: Relatively soft 1Q19 margin, FY19 still unchanged Bekaert: Feedback AGM & company contact Boskalis: 1Q19 trading update with unchanged outlook Celyad: 1Q19 – updates on allo CRC and auto AML mid 2019 EVS: Confirmed its guidance for FY19 GBL: Solid 1Q19 results, NAV +14.1% Ontex: Waiting for the dust to settle Qrf: 1Q19 results: strengthening balance sheet first

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Analyst Day Up Next for Discussion on New Pipeline Candidates

Alan Vandenberghe ...
  • Alexander Makar
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jan Opdecam
  • Joachim Vansanten
  • Lenny Van Steenhuyse
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: ARGX BB, BAMNB NA, BEKB BB, BOKA NA, CYAD BB, EVS BB, GBLB BB, ONTEX BB, QRF BB

Argenx: 1Q19 – further de-risking pipeline with 2 additions BAM Group: Relatively soft 1Q19 margin, FY19 still unchanged Bekaert: Feedback AGM & company contact Boskalis: 1Q19 trading update with unchanged outlook Celyad: 1Q19 – updates on allo CRC and auto AML mid 2019 EVS: Confirmed its guidance for FY19 GBL: Solid 1Q19 results, NAV +14.1% Ontex: Waiting for the dust to settle Qrf: 1Q19 results: strengthening balance sheet first

2 directors sold after exercising options/sold

Two Directors at Argen X Nv sold after exercising options/sold 7,219 shares at between 115.000EUR and 117.830EUR. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is res...

Thanks to a better fundamental star rating, ARGENX SE sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ARGENX SE (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 17, 2019, the closing price was EUR 115.70 and its expected value was estimated at EUR 110.41.

Valérie GASTALDY

Short term view - ARGENX SE : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €82.40 and then €94.80. The break of €58.50 would endanger the trend.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 82,40 € puis 94,80 €. La rupture de 58,50 € mettrait la tendance en danger.

Valérie GASTALDY

Short term view - ARGENX SE : The background trend is clearly bearish.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €58.50. The background trend would be questioned should prices rise above €94.80.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 58,50 €. La tendance de fond serait remise en cause en cas de franchissement de 94,80 €.

Jérôme VINERIER

Analyse moyen terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 94,80 € puis 119,80 €. La rupture de 18,80 € mettrait la tendance en danger.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch